Jon Congleton Sells 15,319 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) CEO Jon Congleton sold 15,319 shares of the stock in a transaction that occurred on Friday, April 11th. The stock was sold at an average price of $12.19, for a total value of $186,738.61. Following the transaction, the chief executive officer now owns 862,289 shares in the company, valued at approximately $10,511,302.91. This trade represents a 1.75 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Mineralys Therapeutics Price Performance

Mineralys Therapeutics stock traded down $0.15 during mid-day trading on Friday, reaching $13.35. 382,306 shares of the company were exchanged, compared to its average volume of 417,708. The company has a fifty day simple moving average of $12.59 and a 200-day simple moving average of $12.35. The firm has a market cap of $866.09 million, a PE ratio of -3.67 and a beta of -0.39. Mineralys Therapeutics, Inc. has a 12 month low of $8.24 and a 12 month high of $18.38.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.00) by $0.02. Sell-side analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets acquired a new stake in shares of Mineralys Therapeutics in the 4th quarter valued at $48,000. ProShare Advisors LLC bought a new position in Mineralys Therapeutics in the fourth quarter valued at about $128,000. China Universal Asset Management Co. Ltd. raised its stake in Mineralys Therapeutics by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,553 shares of the company's stock worth $130,000 after acquiring an additional 989 shares in the last quarter. GAMMA Investing LLC raised its stake in Mineralys Therapeutics by 9,602.2% during the first quarter. GAMMA Investing LLC now owns 8,829 shares of the company's stock worth $140,000 after acquiring an additional 8,738 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD bought a new position in shares of Mineralys Therapeutics in the fourth quarter worth about $145,000. 84.46% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

MLYS has been the topic of several recent research reports. The Goldman Sachs Group lowered their price objective on Mineralys Therapeutics from $28.00 to $24.00 and set a "buy" rating on the stock in a research report on Thursday, February 13th. Guggenheim reaffirmed a "buy" rating on shares of Mineralys Therapeutics in a research report on Monday, February 24th. Finally, HC Wainwright boosted their price objective on shares of Mineralys Therapeutics from $30.00 to $42.00 and gave the company a "buy" rating in a report on Wednesday, April 2nd.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.